Arcturus initiates dosing in Phase 2 studies for CF and OTC deficiency

Arcturus Therapeutics (ARCT) Holdings announced that the first CF and OTC deficiency participants initiated dosing in December 2024, in the company’s Phase 2 multiple ascending dose studies. “We are very pleased with the recent progress in our Phase 2 studies in people with cystic fibrosis and OTC deficiency. ARCT-032 has the potential to address the significant unmet medical need in the CF community for those who do not qualify for or benefit from available treatment options,” said Dr. Pad Chivukula, Chief Scientific Officer of Arcturus Therapeutics. “ARCT-810 is the only mRNA therapy currently in clinical development intended to enable liver cells to produce OTC enzyme and therefore address the underlying cause of OTC deficiency.”